Ovalac

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ovalac

Property Description
Active ingredient Valacyclovir Hydrochloride
Form Oral Tablet / Caplet
Pharmacological class Antiviral, Nucleoside Analogue
Common use Anti-herpesvirus agent
Origin Synthetic Compound

What Type of Medicine is Ovalac?

Ovalac is a prescription-only antiviral drug designated as an anti-herpesvirus agent intended for systemic use against infections caused by the herpes family of viruses. This medication belongs to the nucleoside analogue pharmacological class, distinguishing it as a synthetic compound structurally related to natural molecules used in DNA. The primary purpose of this medicine is to support the body’s defenses by controlling the underlying viral pathogen. The formulation is recognized for its improved oral bioavailability over its predecessor molecule.


Valacyclovir Hydrochloride: The Active Ingredient and Prodrug

The sole active ingredient in Ovalac is Valacyclovir Hydrochloride, which functions as an L-valine ester prodrug of the primary active substance, Acyclovir. This chemical structure is critical because the administered Valacyclovir is initially inactive, requiring rapid conversion by the body's metabolic system after it is taken orally. The drug's prodrug status is a chemical strategy utilized to enhance its absorption and overall concentration in the bloodstream compared to Acyclovir itself. Once ingested, the prodrug is converted to the active drug in the body. Ovalac is typically supplied as an oral tablet or caplet, indicating its intended oral route of administration.


What is the General Purpose of Ovalac?

The general purpose of Ovalac is to inhibit the replication of pathogenic herpesviruses, including the Herpes Simplex Virus (HSV) and Varicella-Zoster Virus (VZV), thereby limiting the spread of infection. This is achieved by the converted active substance, Acyclovir, which is selectively activated inside virus-infected cells. By interfering with the process of viral DNA synthesis, the drug stops the virus from making copies of itself. This action is the foundational principle for managing and controlling acute viral episodes.

Regulatory References

  1. Valacyclovir prodrug conversion in the body
  2. Aciclovir on WHO Essential Medicines List

What side effects are possible with Ovalac?

Possible Side Effects and Safety Information

The safety profile of Ovalac, based on official regulatory documentation, establishes the officially recognized adverse reactions and specific safety considerations. The classification of side effects is determined by regulatory frequency bands, which group reactions from Very Common to Very Rare.

Frequency-Classified Adverse Reactions

Adverse effects are categorized by how frequently they are documented in clinical use:

  • Very Common (ge 1/10): Headache.
  • Common (ge 1/100 to < 1/10): Nausea, abdominal pain, and vomiting are frequently reported.
  • Uncommon (ge 1/1,000 to < 1/100): Includes rash, sometimes involving photosensitivity.
  • Rare/Very Rare (< 1/1,000): These classifications include serious events affecting the nervous system and kidneys, such as confusion, hallucinations, convulsions, and acute renal failure.

System-Organ Classes and Serious Reactions

Side effects are officially documented across several System-Organ Classes, including Nervous System Disorders, Gastrointestinal Disorders, Renal and Urinary Disorders, and Skin and Subcutaneous Tissue Disorders.

The label documents serious adverse reactions, which include Acute Renal Failure and severe Central Nervous System (CNS) effects such as encephalopathy and coma. A specific, very rare serious risk is Thrombotic Thrombocytopenic Purpura/Hemolytic Uremic Syndrome (TTP/HUS), primarily documented in severely immunocompromised patients.

Population-Specific Safety Considerations

The official labeling notes that elderly patients and those with pre-existing renal impairment have an increased susceptibility to both Acute Renal Failure and severe CNS adverse events. These serious CNS effects are generally observed to be dose-related and are typically reversible upon discontinuation of treatment. Regulatory information emphasizes the importance of adequate fluid intake to help prevent the precipitation of the active substance in the renal tubules, a factor that contributes to the risk of acute renal issues.

Overdose and Emergency Response

Overdose involving Ovalac (Valacyclovir Hydrochloride) is formally documented in regulatory sources as primarily affecting the Central Nervous System (CNS) and the Renal System. Manifestations of overdose are often associated with neurotoxicity, which may present as confusion, agitation, hallucinations, seizures, tremor, or, in severe cases, coma. The other major documented consequence is acute renal failure, which can lead to anuria and is linked to the precipitation of the active substance's crystals in the kidney tubules. The development of Thrombotic Thrombocytopenic Purpura (TTP) and Hemolytic Uremic Syndrome (HUS) is also noted in highly immunocompromised patients.

Due to the severity of these potential outcomes, regulatory authorities mandate that patients must seek immediate medical attention or contact a Poison Control Center immediately if an overdose is suspected. This action is critical because the management of severe outcomes, such as acute renal failure, may require immediate procedural steps like hemodialysis to enhance the elimination of the drug, as no specific antidote is known. Official documentation highlights that elderly patients and individuals with pre-existing renal impairment are at a significantly higher risk for developing both severe CNS symptoms and acute renal toxicity. Management is always based on providing symptomatic and supportive care.

Therapeutic Uses of Ovalac

What Ovalac Treats: Main Uses and Benefits

Ovalac is used to provide symptomatic relief across therapeutic domains, offering support when symptoms that interfere with daily functioning are present. This primary function relates to the management of pain and swelling. Ovalac is applied to help manage symptom clusters related to inflammatory or irritative states, such as generalized aches, localized pain, swelling, and stiffness.


Symptom Relief and Contexts of Use

The medication is relevant in clinical settings where supportive symptom management is appropriate, and may be part of symptomatic management in conditions involving episodic or fluctuating manifestations, such as those arising from joints, muscles, or ligaments. It is commonly used in contexts like musculoskeletal discomfort and during acute episodes where symptoms intensify and temporary functional strain is present.

“Ovalac is applied when symptoms create noticeable functional strain, may assist with maintaining comfort during periods of heightened physical stress.”

By easing these symptom clusters, Ovalac helps maintain a sense of stability when symptoms are more noticeable and may support a more manageable experience when routine activities are disrupted. This therapeutic support contributes to easing the overall symptom load, helping to improve day-to-day comfort.


Quick Fact: Relief for Symptoms related to physical discomfort and inflammatory states

Eligibility and Restrictions for Use

Who Can and Cannot Use Ovalac?

The eligibility for Ovalac (Valacyclovir Hydrochloride) is strictly defined by regulatory criteria, focusing on patient status, age, and organ function, as documented in official prescribing information.


Contraindications

Use is prohibited for individuals with a known hypersensitivity or allergy to valacyclovir or its active metabolite, acyclovir. The medicine also must not be used by patients with a documented history of DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms) related to the drug.


Population-Specific Restrictions

The medicine is approved for adults across all labeled indications. Pediatric use is restricted and age-dependent: it is approved for Chickenpox in children aged 2 to <18 years, and Cold Sores in adolescents ge 12 years. Use is not established for other pediatric indications. Patients with renal impairment and elderly patients require conditional use with mandatory dose reduction and close monitoring due to increased neurological risk. High doses are restricted in patients with advanced HIV disease or those who have received organ transplants (e.g., renal, bone marrow) due to the serious risk of TTP/HUS. During pregnancy and lactation, use is conditional and requires formal medical assessment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Ovalac (Valacyclovir) is officially described in regulatory documents based on two primary mechanisms: competitive inhibition of renal clearance and additive toxicity risk.


Pharmacokinetic Interactions

Ovalac's active substance, Acyclovir, is eliminated primarily via the kidneys through active tubular secretion. Co-administration with certain drugs inhibits this process, leading to increased exposure (plasma concentration) of Acyclovir. This is a pharmacokinetic interaction pattern.

  • Probenecid and Cimetidine: Both agents are documented to reduce the renal clearance of Acyclovir, resulting in an officially described increase in the plasma concentration.
  • Co-administration of Probenecid and Cimetidine results in a greater, additive increase in Acyclovir exposure than either drug alone.

Pharmacodynamic and Risk Interactions

  • Nephrotoxic Drugs: Co-administration with other medicines known to be nephrotoxic (e.g., NSAIDs, Cyclosporine) increases the risk of acute renal failure due to combined, additive potential for kidney impairment.
  • Live Vaccines: The co-administration of Ovalac with certain live vaccines (such as Talimogene laherparepvec) may reduce the vaccine's intended effect due to potential antiviral antagonism.

Population-Specific Cautions: Interaction risks are formally heightened in elderly patients and individuals with pre-existing renal impairment, as these populations are more susceptible to the effects of reduced Acyclovir clearance and nephrotoxicity.

Mechanism of Action

Ovalac functions as an agonist for the nuclear Farnesoid X Receptor (FXR), a ligand-activated transcription factor expressed predominantly in the hepatobiliary system and the intestine. The drug’s interaction with FXR leads to its nuclear activation and subsequent transcriptional modulation of target genes. This includes the induction of Small Heterodimer Partner (SHP). SHP then acts to repress the gene encoding cholesterol 7alpha-hydroxylase (CYP7A1), the rate-limiting enzyme in the de novo synthesis of bile acids from cholesterol within the liver. This molecular pathway establishes a coordinated negative feedback loop that reduces the synthesis of endogenous bile acids.

Simultaneously, FXR activation affects bile acid transport by modulating transporters; it reduces the expression of the hepatocellular uptake transporter sodium-taurocholate co-transporting polypeptide (NTCP) and increases the expression of the efflux pump bile salt export pump (BSEP). The combined intracellular consequences—reduced synthesis and modulated transport—result in a system-level physiological modulation characterized by a reconfigured circulating bile acid pool and an alteration in hepatic bile flow dynamics.

Dosage and Administration Information

Ovalac is administered exclusively via the oral route, available as both 500 mg and 1 gram caplets, or as an extemporaneously prepared suspension for patients who cannot take solid forms. The core principle of Ovalac usage is that the dosage and treatment duration are specific to the viral condition being addressed. For example, the short-course regimen for managing recurrent cold sores involves a total daily dose of 4 grams divided into two doses taken 12 hours apart over a single day. In contrast, the treatment of herpes zoster (shingles) requires a lower frequency, typically 1 gram three times daily, but extends over a seven-day course. The usage pattern may also involve chronic suppressive therapy, such as 500 mg or 1 gram once daily, which represents a long-term duration pattern rather than an acute, finite course.

Administration of Ovalac can be completed without regard to meals. A critical administration condition for episodic use is the timely initiation of therapy, which must begin at the earliest recognition of an outbreak, such as the initial tingling or burning sensation. Furthermore, patients with impaired kidney function require dose reduction for all approved indications, as the drug’s elimination is reliant on the renal system. Older adults may also require modification if their renal status is compromised. Throughout the course of use, it is a procedural necessity to maintain adequate hydration to support the proper clearance of the active substance. This reflects a structured approach to use, where adherence to the precise dose, frequency, and duration is a standard component of the treatment regimen.

Recent Clinical Evidence

Ovalac: Recent Clinical Evidence

The clinical investigation of Ovalac (Valacyclovir) has primarily focused on its role as an anti-herpesvirus agent, relying heavily on Randomized Controlled Trials (RCTs) and systematic reviews to describe the observed patterns and outcomes for specific viral infections. Research efforts have explored how symptoms evolve and what physiological changes were measured during defined research periods.


Evidence for use in Herpes Zoster (Shingles)

The research base for Ovalac in the investigation of acute episodes of shingles largely consists of large-scale, comparative RCTs in immunocompetent adults. The studies monitored several outcomes related to acute viral activity and co-occurring nerve-related discomfort. Research examined the time needed for skin lesions to reach full crusting or healing and tracked the frequency and persistence of Postherpetic Neuralgia (PHN). Research protocols typically focused on participants who initiated the study regimen quickly after the rash appeared; measurements or findings for patients who delay starting the regimen are less extensive.


Evidence for use in Genital Herpes

Evidence for Ovalac was studied across two main research scenarios: in the context of acute outbreaks and chronic suppressive therapy. Studies for acute outbreaks examined outcomes related to lesion healing and the duration of patient-reported discomfort. For suppressive therapy, long-term RCTs explored outcomes by measuring the frequency of clinical recurrences over the course of a year and monitoring the rate of asymptomatic viral shedding.


Research in Specific Patient Groups and Gaps

Ovalac was evaluated in older adults for shingles and in HIV-infected adults for suppressive regimens. Conversely, data for certain groups remain insufficient. Research evidence for children under 12 years of age has not been reported in the core regulatory documentation for cold sores. Furthermore, long-term effects are not fully established regarding the durability of the effect after continuous suppressive therapy is stopped.

Key Studies & References

  1. Clinical Trials Database and Research Summaries (NIH/NLM)
  2. Meta-analysis of Valacyclovir for the Suppression of Genital Herpes Recurrence
  3. Clinical Guideline for the Management of Varicella (Chickenpox)

Frequently Asked Questions (FAQ)

Common questions about Ovalac (FAQ)

Q: How quickly should I expect to see an effect from Ovalac?

A: Official information stresses that starting treatment at the earliest recognition of symptoms is emphasized, as delaying the start of the medication may reduce its effectiveness. Studies indicate the medication is intended to lessen symptoms of the infection and help sores heal faster.

Q: What is the difference between Ovalac and other drugs in the same class?

A: Regulatory documents state that Ovalac is a prodrug of the active substance, Acyclovir, which is its predecessor molecule. This means Ovalac is chemically converted into Acyclovir inside the body. This specific structure is described as enhancing the medicine's absorption and overall bioavailability compared to taking Acyclovir directly.

Q: Why are there different strengths of the Ovalac tablet?

A: The medicine is available in different strengths, such as the 500 mg and 1 gram tablets, because the required dosage and treatment duration are highly specific. This necessitates the various tablet strengths to accommodate the different regimens outlined in the official prescribing information.

Q: Are there any long-term health risks associated with taking Ovalac?

A: Official documents note that a serious, very rare risk known as Thrombotic Thrombocytopenic Purpura/Hemolytic Uremic Syndrome (TTP/HUS) has been documented in certain populations. This risk is primarily seen in severely immunocompromised patients, such as those with advanced HIV disease. Other serious effects are generally reversible upon stopping the medication.

Q: Can Ovalac interact with common over-the-counter pain relievers?

A: The official interaction profile notes that taking Ovalac with medicines known to be nephrotoxic (kidney-harming), which includes common NSAIDs, increases the potential risk of acute renal failure. Patients are often advised to discuss the use of any common pain relievers with their doctor.

Q: Does Ovalac have any known effect on a person's mood or focus?

A: Side effects reported in clinical use include serious Central Nervous System (CNS) effects such as confusion, hallucinations, and agitation. Less common reactions have included patients reporting trouble concentrating, feelings of discouragement, and irritability. Elderly patients and those with kidney issues may have increased susceptibility to these effects.

Q: Is Ovalac the same as [Name of a similar common drug]?

A: Ovalac is the brand name for Valacyclovir, which is a prodrug of Acyclovir. While chemically related to Acyclovir, it is not the same medicine. Its specific formulation is designed for better absorption into the bloodstream compared to its predecessor.

Q: Can the effectiveness of Ovalac wear off over time?

A: The official drug information states that the possibility of viral resistance to the active substance has been noted. This occurs in some patients who show a poor clinical response during the course of treatment, and regulatory documentation indicates that this is a potential issue that may be monitored by the prescriber.

Q: Are there specific times of day that are best for taking Ovalac?

A: The official instructions indicate the medication is scheduled based on frequency (e.g., once or multiple times a day) as prescribed for your condition. Furthermore, the official label states that the medication can be taken without regard to meals, offering flexibility in timing the doses.

Q: What precautions should be taken when driving while on Ovalac?

A: Official patient information notes that if the medication causes dizziness or drowsiness, activities requiring mental alertness, such as driving or operating heavy machinery, should be avoided until the effects of the medicine are known.

Q: What are the signs that Ovalac is starting to work for me?

A: The general purpose of the medication, as defined in regulatory documents, is to limit the spread of the viral infection. The resulting action should be observable as lessened symptoms of the outbreak and helping the sores or lesions to heal faster than they would without treatment.

Q: Why do some people stop taking Ovalac?

A: The drug must be stopped if a patient develops a known contraindication, such as a severe allergic reaction like DRESS. Furthermore, serious side effects, including acute renal failure or severe confusion, typically necessitate the discontinuation of the medication.

Q: What is the typical dosage range described in the official label for Ovalac?

A: The official label notes that the dosage of Ovalac is condition-specific and highly variable. The typical dosing pattern ranges from high-dose, short-term regimens for acute outbreaks to lower-dose regimens used for chronic suppressive therapy.

Q: Is Ovalac considered a new or established treatment?

A: Ovalac is considered an established anti-herpesvirus agent. As a prodrug of the widely used Acyclovir, its utility and safety are based on multiple clinical trials and regulatory approvals for treating various viral infections across different patient groups.

Q: Is it common to feel tired when starting Ovalac?

A: Yes, regulatory documents list feeling tired or weak (fatigue) among the commonly reported side effects of the medicine. Patients experiencing severe or persistent side effects should discuss these with their healthcare provider.

Q: What happens if I miss a scheduled time for Ovalac?

A: Official patient information notes that a missed dose can be taken when remembered, but patients are cautioned against taking two doses at the same time. Specific guidance on missed doses should be confirmed with the prescribing professional.

Q: Is Ovalac available as a generic medicine?

A: Yes, official regulatory records confirm that the drug is available as both the brand-name product (Valtrex) and as a generic medicine (valacyclovir) through various manufacturers.

Q: Why is Ovalac sometimes called by another name?

A: The medicine has both a brand name (Ovalac, or Valtrex) and a generic name (Valacyclovir) for its active ingredient. Official regulatory documents often refer to it by the generic name, while the brand name is used for the originally manufactured product.

Q: What is the full list of ingredients in an Ovalac tablet?

A: The full list includes the active substance (Valacyclovir Hydrochloride) and various inactive ingredients used in the tablet formulation. The prescribing information lists all ingredients, which is important for individuals with known allergies.

Q: Do lifestyle changes still matter while taking Ovalac?

A: Official patient counseling information advises that even when taking the medicine, it does not prevent the spread of certain viruses, particularly genital herpes. Therefore, it remains important to observe appropriate precautions, such as using barrier methods.

Q: Can I take vitamins or supplements while on Ovalac?

A: Official patient information indicates that a healthcare provider should be informed about all vitamins, supplements, and natural products being taken before starting the medication. This allows for screening of potential interactions.

Q: Is there a risk of dependence or withdrawal with Ovalac?

A: No. According to official safety advice and regulatory classification, the medicine is not habit-forming. There is no recognized risk of physical dependence or withdrawal associated with its typical use.

Q: Are there any specific foods to avoid when taking Ovalac?

A: Official drug information states that Ovalac is not known to interact with foods and can be taken without regard to meals. There are no specific foods that need to be avoided during treatment.

Q: Does Ovalac have a Boxed Warning in its prescribing information?

A: Official FDA labeling indicates that the medicine does not carry a Boxed Warning (the highest safety alert) in its current prescribing information.

Q: Can Ovalac affect the results of lab tests?

A: The medicine can potentially affect the results of certain laboratory tests. For this reason, doctors may request blood and urine tests to check for any unwanted effects on kidney function or other potential changes during the course of treatment.

Q: What research is being done on new uses for Ovalac?

A: Current research efforts documented in governmental clinical trial databases are examining the use of Ovalac for conditions outside of its original approved indications. For example, some studies are exploring its potential role in patients with Mild Cognitive Impairment (MCI).

Q: Can I use alcohol while I am being treated with Ovalac?

A: Official patient information notes that patients may be advised to limit alcoholic beverages. This caution is primarily due to the risk that alcohol may worsen side effects such as dizziness, especially when combined with the potential for Central Nervous System (CNS) adverse reactions from the medication.

Q: What should I do if a side effect of Ovalac bothers me?

A: Official guidance indicates that patients should seek immediate attention for any serious side effects documented on the label. Patients should also discuss any severe or concerning effects that do not go away with their healthcare provider.

Q: Does Ovalac interact with common herbal products?

A: Although specific interactions may not be fully documented, official patient information advises patients to tell their doctor or pharmacist about any herbal products or supplements they take. This is a general precaution to help prevent unforeseen drug interactions.

Q: Is it normal to feel a change in appetite with Ovalac?

A: Yes, a lack of appetite is listed among the commonly reported side effects of the medicine in official regulatory documentation. Any significant or concerning change in appetite should be discussed with a healthcare provider.

How should Ovalac be stored and disposed of?

The storage and disposal of Ovalac (Valacyclovir Hydrochloride) must adhere strictly to the conditions specified in official regulatory labeling to ensure product stability and safety.

Required Storage Conditions

  • Temperature: Store the oral tablets at Controlled Room Temperature, which is defined as 20 C to 25 C (68 F to 77 F). The medicine must not be frozen.
  • Environmental Protection: The product must be stored in its original container, which must be tight and light-resistant, to protect the tablets from moisture and light. Do not use the medicine after the expiry date.
  • Child Safety: Ovalac must be kept out of the sight and reach of children to prevent accidental ingestion.

Disposal Instructions

Unused or expired Ovalac must be disposed of according to local regulations for pharmaceutical waste. Do not discard the tablets in household waste, pour them down the drain, or flush them down the toilet, unless explicitly authorized by a national regulatory authority.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ovalac found in:

A-Z Index: